The provider universe
This page's job is completeness. Rankings persuade; a directory enumerates. Every company below gets the same 18-field record in our ledger; profile depth and dated dollar figures land as each provider is read on its own pages (nine were, on 2026-09-17) and clears verification. Structural facts shown here reflect our latest review and can change — the profile page carries the authoritative dated record.
The field at a glance — all 18, linked
| Provider | Model | Molecules | Formats | Price status | Care signal | Watch-fors |
|---|---|---|---|---|---|---|
| NexLife | Flat-rate compounded | Sema + tirz (+ microdose, ODT) | Injectable vials; ODT | Verified 2026-09-17: $119–169/mo by molecule & term, every plan charged monthly | CARE360 included; laboratory review not stated on the plan pages (read September 17, 2026) | ODT lacks outcome trials |
| Ro | Brand access + insurance nav | Brand only on the page read (no compounded price printed) | Brand pills, pens, vials | Read 2026-09-17: semaglutide (brand) $298/mo all-in; tirzepatide (brand) $448/mo all-in | PA support; established platform | Fee billed beside the brand price; medication rises with the dose |
| Hims | DTC platform, “personalized” compounded | Brand only on the page read (no compounded price printed) | Brand pills, pens, vials | Read 2026-09-17: semaglutide (brand) $298/mo all-in; tirzepatide (brand) $448/mo all-in | Questionnaire-first at scale | Fee billed beside the brand price; medication rises with the dose |
| Hers | Women-positioned DTC | Brand only on the page read (no compounded price printed) | Brand pills, pens, vials | Read 2026-09-17: semaglutide (brand) $298/mo all-in; tirzepatide (brand) $448/mo all-in | Same platform as Hims | Fee billed beside the brand price; medication rises with the dose |
| Henry Meds | Flat-rate compounded (claimed) | Compounded sema + tirz | Injectable | Read 2026-09-17: tirzepatide $349/mo | Telehealth standard | Flat claim untested; terms fine print |
| Orderly Meds | Format breadth | Compounded sema + tirz | Injectables + oral tiers | Pending | Breadth-first | Tier complexity; oral evidence gap |
| Found | Coaching + insurance program | Program-dependent access | Varies | Read 2026-09-17: no rankable price printed — listed, not ranked | Structured coaching | Program-fee vs med-cost split |
| Mochi Health | Specialist membership | Clinician-directed (brand or compounded) | Varies | Read 2026-09-17: semaglutide $178/mo all-in; tirzepatide $278/mo all-in | Obesity-medicine specialists; labs-friendly | Membership + med total opacity |
| Noom Med | Behavior app + med layer | Brand routing (+policy-dependent) | Brand; varies | Read 2026-09-17: semaglutide (microdose) $179/mo | Daily behavioral structure | App-fee vs med split |
| WeightWatchers Clinic | Legacy program + prescribing | Brand routing via clinicians | Brand; varies | Read 2026-09-17: no rankable price printed — listed, not ranked | Workshop/community pedigree | Post-restructuring terms; bundle split |
| LifeMD | Public telehealth, brand + insurance | Brand only on the page read (no compounded price printed) | Brand pills, pens, vials | Read 2026-09-17: semaglutide (brand) $348/mo all-in; tirzepatide (brand) $448/mo all-in | Insurance billing; filings-level candor | Fee billed beside the brand price; medication rises with the dose |
| PlushCare | Insurance-first primary care | Brand via normal channels | Brand | Pending | In-network visits; PA machinery | Membership mechanics; visit costs |
| Amazon One Medical | Retail primary care + pharmacy rails | Brand via Amazon Pharmacy | Brand | Pending | Records + logistics continuity | Generalist depth; fee path clarity |
| Ivim Health | App care-team, mixed routes | Brand + compounded menu | Varies by route | Pending | Messaging-forward care | Route-dependent sourcing questions |
| Fridays | GLP-1-native DTC | Brand + compounded menu | Varies by route | Pending | Streamlined intake | Young-brand continuity; teaser risk |
| Remedy Meds | Price-led DTC | Compounded claims | Injectable | Pending | Thin documentation | Doc-gap tier |
| Shed | Price-led DTC | Compounded claims | Injectable | Pending | Thin documentation | Doc-gap tier |
| Fifty 410 | Sparse-documentation entrant | Compounded claims | Unclear | Pending | Thin documentation | Doc-gap tier |
Structural status only — scores and dollar figures appear as verification fills each row; every provider name links to its full profile and diligence script. The 2026-08 additions (queue #11–17) are the U.S. News-rated branded platforms, per their release.
Sam LLC has a material business relationship with NexLife and earns affiliate commissions from some listed providers. Inclusion in this directory is free and universal; no provider can pay to be added, removed, or reordered. Details.
NexLife
Flat-rate compounded GLP-1 programs across standard, microdose, and sublingual ODT protocols. Distinguishing structure: the same price at every dose (plan pages read September 17, 2026), $0 membership/consult fees, CARE360 support included, cancel any time (NexLife FAQ, read September 17, 2026). Injectable tirzepatide from $139/mo (12-mo plan); semaglutide from $119/mo. Full profile →
Mochi Health
Obesity-medicine telehealth built on a monthly clinical membership plus separately billed medication through partner pharmacies; known for board-certified obesity specialists and an active stance on personalized compounded dosing. Pricing, states, and cancellation terms: pending verification against checkout.
Orderly Meds
Direct-to-consumer compounded GLP-1 programs with bundled provider access; markets multiple formats including oral options. Formulation sourcing and true-cost fields pending verification.
Ro
Large telehealth platform; post-2025 emphasis on FDA-approved brand access (Zepbound, Wegovy — including manufacturer-direct vial integration) with insurance navigation and cash-pay pathways. Strongest fit in our taxonomy: insurance-first candidates.
Hims
Mass-market telehealth; weight programs centered on compounded semaglutide offerings and brand pathways, with well-publicized manufacturer-partnership turbulence in 2025. Current formulation lineup and pricing pending verification.
Hers
Sister platform to Hims focused on women's health; weight-loss programs with compounded semaglutide and lifestyle support. Fields pending verification.
Henry Meds
One of the earliest large compounded-GLP-1 telehealth brands; flat-subscription positioning. Post-shortage formulation strategy and current legal posture: pending verification.
Remedy Meds
DTC weight-loss telehealth marketing bundled GLP-1 programs. Pharmacy partners and true-cost fields pending verification.
Shed
Subscription weight-loss telehealth with compounded GLP-1 offerings. Fields pending verification.
Found
Weight-care platform pairing medication pathways (brand and, historically, compounded) with behavioral programming and insurance navigation. Fields pending verification.
Fifty 410
Smaller DTC GLP-1 telehealth brand — exactly the kind of lesser-covered candidate this directory exists to surface. Full record pending verification.
Missing a provider? The directory's usefulness is completeness — submissions welcome via the corrections process on any page. New entries start at "verification queued" like everyone else.